Skip to main content
SpringerLink
Log in

Economic Evaluation of Pharmaceuticals

Science or Marketing?

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

An Erratum to this article was published on 01 March 1992

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Anon. Farewell to promoting good buys? Lancet 338: 416–417, 1991

  • Buxton MJ, Drummond MF. Quality of life measurement in the development of medicines. Pharmaceutical Journal 244: 260–262, 1989

    Google Scholar 

  • Commonwealth of Australia Guidelines for submissions to the Pharmaceutical Benefits Advisory Committee: including economic analyses. Woden (ACT), Commonwealth of Australia, 1990

  • Department of Health. Improving prescribing. Department of Health, London, 1990

    Google Scholar 

  • Drummond MF. European Community Project on the methodology of economic appraisal of health technology: proposals for concerted action. Brussels, European Community, 1990

    Google Scholar 

  • Drummond MF. Output measurement for resource allocation decisions in health care. Oxford Review of Economic Policy 5(1): 59–74, 1989

    Article  Google Scholar 

  • Drummond MF, Brandt A, Luce BR, Rovira, J. Standardizing economic evaluations in health care: practice, problems and potential. International Journal of Technology Assessment in Health Care, in press, 1991.

    Google Scholar 

  • Drummond MF, Davies LM. Economic analysis alongside clinical trials: revisiting the methodological issues. International Journal of Technology Assessment in Health Care, in press, 1991

    Google Scholar 

  • Drummond MF, Heyse J, Cook J, McGuire A. Selection of end-points in economic evaluations of coronary heart disease interventions. Paper presented at the Seventh Annual Meeting of the International Society of Technology Assessment in Health Care, Helsinki, June 23–26, 1991

  • Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, Oxford University Press, Oxford, 1987

    Google Scholar 

  • Graham DY, Agrawal NW, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre double-blind placebo-controlled trial. Lancet 2: 1277–1280, 1988

    Article  PubMed  CAS  Google Scholar 

  • Henry D. Economic analysis as an aid to reimbursement decisions: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1(1): ((pagination to come)), 1992

    Google Scholar 

  • Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324(19): 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Jackuck SJ, Brierley H, Jackuck S, Willcox PM. The effect of hypotensive drugs on quality of life. College of General Practitioners 32: 103–105, 1982

    Google Scholar 

  • Loomes G, McKenzie L. The use of QALYs in health care decision making. Social Science and Medicine 28: 299–308, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mehrez A, Gafni A. Quality adjusted life years, utility theory and healthy years equivalent. Medical Decision Making 9: 142–149, 1989

    Article  PubMed  CAS  Google Scholar 

  • Peto R. ISIS-3 shows similar results with different thrombolytic agents. American Family Physician 43(5): 747, 1991

    Google Scholar 

  • Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Little Brown and Co., Toronto and New York, 1985

    Google Scholar 

  • Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care: principles, practice and potential. Health Administration Press, Ann Arbor, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Health Economics, University of York, York, 501 YDD, England

    Michael F. Drummond

Authors
  1. Michael F. Drummond
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03259886.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drummond, M.F. Economic Evaluation of Pharmaceuticals. Pharmacoeconomics 1, 8–13 (1992). https://doi.org/10.2165/00019053-199201010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199201010-00004

Keywords

Search

Navigation